Altris AI is excited to announce a new solution for clinical and pre-screening trials, created in partnership with Bitfount.
This collaboration delivers advanced AI products tailored for retinal conditions such as Wet and Dry AMD, GA, DR, DME, and inherited retinal diseases. By deploying AI models directly on reading center servers or on-site, the solution enhances trial speed while prioritizing data privacy, allowing researchers to conduct secure, efficient analyses without transferring sensitive patient data externally.
This collaboration delivers advanced AI products tailored for retinal conditions such as Wet and Dry AMD, GA, DR, DME, and inherited retinal diseases. By deploying AI models directly on reading center servers or on-site, the solution enhances trial speed while prioritizing data privacy, allowing researchers to conduct secure, efficient analyses without transferring sensitive patient data externally.
Join Altris AI this week at Booth 4058 at the American Academy of Ophthalmology event to explore how their technology helps detect and track over 70 retinal pathologies, enhancing diagnostic precision and privacy.